The only injectable influenza vaccine facility in the UK, the plant utilises egg-based and adjuvant technology for seasonal, pre-pandemic and pandemic vaccines.

The CSL Seqirus Liverpool site is a centre of excellence for the manufacture of enhanced influenza vaccines and plays an important part in providing pandemic preparedness and response for the UK and other countries in Europe. An egg-based bulk manufacturing facility, Liverpool produces seasonal influenza vaccine distributed across the northern and southern hemispheres. With over 620 employees, it is one of the biggest biotechnology sites in Europe.

The largest cell-based influenza vaccine manufacturing facility in the world, with advanced technology successfully producing at commercial scale.

This CSL Seqirus Holly Springs facility was purpose-built in partnership with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to help combat pandemic threats. The public-private partnership is the first in the world to establish cell-based technology as a highly scalable method of production. Additionally, the facility produces the CSL Seqirus proprietary adjuvant, MF59®, which can have a dose-sparing effect, thereby further boosting the output of influenza vaccine during a pandemic emergency. Holly Springs has capacity for formulation, fill and finish manufacturing of seasonal influenza vaccines for global markets.

The only influenza vaccine manufacturing facility in Australia and the world’s only manufacturer of Q fever vaccine and local antivenoms.

Based in Melbourne, Parkville uses egg-based influenza vaccine manufacture for seasonal, pre-pandemic and pandemic vaccine production to Australia and worldwide markets. The facility also plays a key role in the global fight against influenza by developing candidate vaccine viruses for the World Health Organisation in the Asia Pacific region. CSL Seqirus also plays a unique public health role, continuing a long legacy as the manufacturer and sole supplier of a range of products made in the national interest for the Australian Government, including antivenoms and Q fever vaccine.